Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lineage Cell Therapeutics (LCTX) Interest & Investment Income: 2014-2024

Historic Interest & Investment Income for Lineage Cell Therapeutics (LCTX) over the last 10 years, with Dec 2024 value amounting to $1.7 million.

  • Lineage Cell Therapeutics' Interest & Investment Income fell 7.81% to $366,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year decrease of 2.03%. This contributed to the annual value of $1.7 million for FY2024, which is 5.28% up from last year.
  • Latest data reveals that Lineage Cell Therapeutics reported Interest & Investment Income of $1.7 million as of FY2024, which was up 5.28% from $1.6 million recorded in FY2023.
  • Lineage Cell Therapeutics' 5-year Interest & Investment Income high stood at $1.7 million for FY2024, and its period low was $829,000 during FY2022.
  • Moreover, its 3-year median value for Interest & Investment Income was $1.6 million (2023), whereas its average is $1.4 million.
  • As far as peak fluctuations go, Lineage Cell Therapeutics' Interest & Investment Income crashed by 38.34% in 2020, and later skyrocketed by 96.50% in 2023.
  • Over the past 4 years, Lineage Cell Therapeutics' Interest & Investment Income (Yearly) stood at $1.0 million in 2020, then reached $829,000 in 2022, then surged by 96.50% to $1.6 million in 2023, then increased by 5.28% to $1.7 million in 2024.